M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE(-/-) mice
Elyse Di Marco,Elyse Di Marco,Stephen P. Gray,Stephen P. Gray,Phyllis Chew,Kit Kennedy,Mark E. Cooper,Harald H.H.W. Schmidt,Karin Jandeleit-Dahm,Karin Jandeleit-Dahm +9 more
TL;DR: Findings demonstrate distinct roles for NOX4 and NOX1 in immune-inflammatory responses that drive atherosclerosis in the aortic sinus of diabetic mice.
Journal ArticleDOI
Apolipoprotein E genotype is associated with serum C-reactive protein but not abdominal aortic aneurysm
TL;DR: An association between ApoE genotype and serumCRP was confirmed and the varepsilon4 allele was associated with lower serum CRP under a dominant model, adjusting for other risk factors plus serum creatinine.
Patent
QTL "mapping as-you-go"
TL;DR: In this paper, the authors provide methods for monitoring QTL effects and marker assisted selection (MAS) involving providing a recursively determined correlation between one or more markers and a phenotype of interest.
Journal ArticleDOI
Structure aided design of chimeric antibiotics.
Tomislav Karoli,Sreeman K. Mamidyala,Johannes Zuegg,Scott R. Fry,Ernest H. L. Tee,Tanya A. Bradford,Praveen K. Madala,Johnny X. Huang,Soumya Ramu,Mark S. Butler,Mark E. Cooper +10 more
TL;DR: A chimeric approach using click chemistry where the pharmacophores of two drugs are overlapped into a single smaller, more drug-like molecule is developed, which shows modest, but broad spectrum activities against drug sensitive and resistant Gram-negative and Gram-positive bacteria.
Journal ArticleDOI
Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes
Toshiaki Ohkuma,Min Jun,John Chalmers,Mark E. Cooper,Pavel Hamet,Stephen B. Harrap,Sophia Zoungas,Sophia Zoungas,Vlado Perkovic,Mark Woodward,Mark Woodward +10 more
TL;DR: Clinically meaningful decreases in eGFR and increases in UACR over 2 years, independently and in combination, were significantly associated with higher risk of major clinical outcomes.